Healios Prioritizes ARDS Clinical Trials Over Stroke Lead Drug HLCM051

MT Newswires Live

Dec 09

Healios (TYO:4593)will submit a clinical trial application for a global Phase 3 Acute Respiratory Distress Syndrome (ARDS) study in early 2026, according to its Tokyo bourse filing on Tuesday.

The group said this after shifting its development strategy for the regenerative medicine HLCM051 (invimestrocel), now prioritizing its advancement as a treatment for ARDS in the near term.

Concurrently, Healios has decided not to pursue a rolling submission for conditional approval of HLCM051 for ischemic stroke by the end of 2025 or early 2026, citing ongoing regulatory discussions and the need to allocate resources effectively.

The company will continue its dialogue with regulators to reevaluate the stroke program's development path at a later date.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2590312566"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2590312566\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2590312566?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-09 18:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590312566","market":"hk","top_or_hot":-1,"title":"Healios Prioritizes ARDS Clinical Trials Over Stroke Lead Drug HLCM051","media":"MT Newswires Live","content":"<html><body><p> Healios (TYO:4593)will submit a clinical trial application for a global Phase 3 Acute Respiratory Distress Syndrome (ARDS) study in early 2026, according to its Tokyo bourse filing on Tuesday.</p><p>The group said this after shifting its development strategy for the regenerative medicine HLCM051 (invimestrocel), now prioritizing its advancement as a treatment for ARDS in the near term.</p><p>Concurrently, Healios has decided not to pursue a rolling submission for conditional approval of HLCM051 for ischemic stroke by the end of 2025 or early 2026, citing ongoing regulatory discussions and the need to allocate resources effectively.</p><p>The company will continue its dialogue with regulators to reevaluate the stroke program's development path at a later date.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Healios Prioritizes ARDS Clinical Trials Over Stroke Lead Drug HLCM051</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHealios Prioritizes ARDS Clinical Trials Over Stroke Lead Drug HLCM051\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-09 18:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Healios (TYO:4593)will submit a clinical trial application for a global Phase 3 Acute Respiratory Distress Syndrome (ARDS) study in early 2026, according to its Tokyo bourse filing on Tuesday.</p><p>The group said this after shifting its development strategy for the regenerative medicine HLCM051 (invimestrocel), now prioritizing its advancement as a treatment for ARDS in the near term.</p><p>Concurrently, Healios has decided not to pursue a rolling submission for conditional approval of HLCM051 for ischemic stroke by the end of 2025 or early 2026, citing ongoing regulatory discussions and the need to allocate resources effectively.</p><p>The company will continue its dialogue with regulators to reevaluate the stroke program's development path at a later date.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2590312566","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590312566","pubTimestamp":1765274449,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Healios will submit a clinical trial application for a global Phase 3 Acute Respiratory Distress Syndrome  study in early 2026, according to its Tokyo bourse filing on Tuesday.The group said this after shifting its development strategy for the regenerative medicine HLCM051 , now prioritizing its advancement as a treatment for ARDS in the near term.Concurrently, Healios has decided not to pursue a rolling submission for conditional approval of HLCM051 for ischemic stroke by the end of 2025 or early 2026, citing ongoing regulatory discussions and the need to allocate resources effectively.The company will continue its dialogue with regulators to reevaluate the stroke program's development path at a later date.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ARDS":"Aridis制药"},"translate_title":"Healios优先考虑ARDS临床试验，而不是卒中先导药物HLCM051","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARDS":1.5},"content_text":"Healios (TYO:4593)will submit a clinical trial application for a global Phase 3 Acute Respiratory Distress Syndrome (ARDS) study in early 2026, according to its Tokyo bourse filing on Tuesday.The group said this after shifting its development strategy for the regenerative medicine HLCM051 (invimestrocel), now prioritizing its advancement as a treatment for ARDS in the near term.Concurrently, Healios has decided not to pursue a rolling submission for conditional approval of HLCM051 for ischemic stroke by the end of 2025 or early 2026, citing ongoing regulatory discussions and the need to allocate resources effectively.The company will continue its dialogue with regulators to reevaluate the stroke program's development path at a later date.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}